

2. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered orally.

3. (Original) The method of claim 2, wherein said conjugated linoleic acid is administered in a unit dosage form.

4. (Original) The method of claim 3, wherein said unit dosage form is a food product.

5. (Original) The method of claim 1, wherein said conjugated linoleic acid is selected from the group consisting of 9,11-octadecadienoic acid, esters thereof, geometric isomers thereof, salts thereof and mixtures thereof.

6. (Original) The method of claim 5, wherein said geometric isomers have configurations selected from the group consisting of trans,trans; cis,cis; trans,cis; and cis,trans.

7. (Original) The method of claim 1, wherein said conjugated linoleic acid is selected from the group consisting of 10,12-octadecadienoic acid, esters thereof, geometric isomers thereof, salts thereof and mixtures thereof.

8. (Original) The method of claim 7, wherein said geometric isomers have configurations selected from the group consisting of trans,trans; cis,cis; trans,cis; and cis,trans.

9. (Previously presented) The method of claim 1, wherein said conjugated linoleic acid is comprised predominantly of cis,trans-9,11-octadecadienoic acid and trans,cis-octadecadienoic acid.

10. (Previously presented) The method of claim 1, wherein said conjugated linoleic

acid is comprised predominantly of cis,cis-9,11-octadecadienoic acid.

11. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered in an amount of about 1 mg of said conjugated linoleic acid/kg body weight to about 10,000 mg of said conjugated linoleic acid/kg body weight.

12. (Original) The method of claim 1, wherein said animal is a mammal.

13. (Original) The method of claim 12, wherein said mammal is a human.

14. (Original) The method of claim 1, wherein said conjugated linoleic acid is administered in a pharmaceutically acceptable carrier medium.

15. (Original) The method of claim 14, wherein said pharmaceutically acceptable carrier medium includes water.

16-21. Cancelled.

22. (Currently amended) A method of treating symptoms of glucose intolerance and elevated plasma insulin of diabetes in a human with type II diabetes mellitus comprising:

a) providing

- i) a therapeutically effective amount of conjugated linoleic acid; and
- ii) a human patient with type II diabetes mellitus suffering from diabetes; and

b) administering said therapeutically effective amount of conjugated linoleic acid to said human diabetic patient under conditions such that said symptoms of diabetes are treated by normalizing glucose tolerance and reducing plasma insulin and glucose levels.

Please add the following claims 23-24: